Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.42 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 3/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4057170 | 0.77 | SYK (0.74) | SYK | |
| SCHEMBL4058473 | 0.69 | AURKA (0.42) | SYK | |
| SCHEMBL4263825 | 0.68 | LRRK2 (0.43) | SYKALDH1A1 | |
| SCHEMBL4717608 | 0.68 | SYK (0.47) | SYKALDH1A1 | |
| SCHEMBL12891510 | 0.66 | ALDH1A1 (0.69) | LMNACHKAMC4RALDH1A1 | |
| SCHEMBL4065544 | 0.66 | SYK (0.48) | SYKALDH1A1 | |
| SCHEMBL29173652 | 0.66 | CHKA (0.58) | HTR6HDAC6LMNACHKAMC4R | |
| SCHEMBL2930691 | 0.65 | LMNA (0.50) | HTR6HRH3HDAC6LMNACHKA | |
| SCHEMBL578497 | 0.64 | LMNA (0.67) | HDAC6LMNACHKAMC4RALDH1A1 | |
| SCHEMBL22844234 | 0.64 | CHKA (0.54) | HTR6HRH3HDAC6LMNACHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794148-B1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7501410-B2 | Methods of inhibiting BTK and SYK protein kinases | ROCHE PALO ALTO LLC (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1998777-A1 | METHODS OF INHIBITING BTK AND SYK PROTEIN KINASES | F. Hoffmann-La Roche AG (CH) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107469-A1 | METHODS OF INHIBITING BTK AND SYK PROTEIN KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219195-A1 | e.g. 4-(5-Methyl-2H-pyrazole-3-ylamino)-phenyl-2H-phthalazin-1-one2-Phenyl-2,3-dihydro-phthalazine-1,4-dione; tyrosine kinase inhibitor; antiinflammatory agent; asthma, rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis | ROCHE PALO ALTO LLC | 2007-09-20 | — | — | US | disclosed |
| US-7226923-B2 | Phthalazinone derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060089359-A1 | Phthalazinone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089359-A1 | Phthalazinone derivatives | SDHA, SDHB, CYP3A5 | IDO1 2810/4885TDO2 3434/4885IDO2 2573/4885 |
| US-20070219195-A1 | e.g. 4-(5-Methyl-2H-pyrazole-3-ylamino)-phenyl-2H-phthalazin-1-one2-Phenyl-2,3-dihydro-phthalazine-1,4-dione; tyrosine kinase inhibitor; antiinflammatory agent; asthma, rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis | SYK, BTK, LCK | IDO1 391/4885TDO2 1590/4885IDO2 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.